AR043241A1 - COMBINED THERAPY THAT INCLUDES AN INDOLPIRROL-CARBAZOL DERIVATIVE AND ANOTHER ANTITUMORAL AGENT - Google Patents
COMBINED THERAPY THAT INCLUDES AN INDOLPIRROL-CARBAZOL DERIVATIVE AND ANOTHER ANTITUMORAL AGENTInfo
- Publication number
- AR043241A1 AR043241A1 ARP040100529A ARP040100529A AR043241A1 AR 043241 A1 AR043241 A1 AR 043241A1 AR P040100529 A ARP040100529 A AR P040100529A AR P040100529 A ARP040100529 A AR P040100529A AR 043241 A1 AR043241 A1 AR 043241A1
- Authority
- AR
- Argentina
- Prior art keywords
- indolpirrol
- combined therapy
- antitumoral agent
- carbazol derivative
- another
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 abstract 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960004117 capecitabine Drugs 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Método para el tratamiento del cáncer en un sujeto que necesita dicho tratamiento, y dicho método comprende la administración al paciente de una cantidad terapéuticamente eficaz de edotecarina junto con capecitabina o docetaxel. Composiciones farmacéuticas y kit terapéutico que las contienen.A method for the treatment of cancer in a subject in need of such treatment, and said method comprises the administration to the patient of a therapeutically effective amount of edquerin together with capecitabine or docetaxel. Pharmaceutical compositions and therapeutic kit containing them.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000317A ITMI20030317A1 (en) | 2003-02-21 | 2003-02-21 | COMBINED THERAPY INCLUDING AN INDOLOPIRROLOCARBAZOLO DERIVATIVE AND ANOTHER ANTI-CANCER AGENT. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043241A1 true AR043241A1 (en) | 2005-07-20 |
Family
ID=32894164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100529A AR043241A1 (en) | 2003-02-21 | 2004-02-20 | COMBINED THERAPY THAT INCLUDES AN INDOLPIRROL-CARBAZOL DERIVATIVE AND ANOTHER ANTITUMORAL AGENT |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1599210A1 (en) |
| JP (1) | JP2006518355A (en) |
| AR (1) | AR043241A1 (en) |
| BR (1) | BRPI0407642A (en) |
| CA (1) | CA2516097A1 (en) |
| CL (1) | CL2004000319A1 (en) |
| IT (1) | ITMI20030317A1 (en) |
| MX (1) | MXPA05008879A (en) |
| TW (1) | TW200500073A (en) |
| WO (1) | WO2004073719A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007307080B2 (en) * | 2006-10-06 | 2014-01-09 | Bavarian Nordic A/S | Methods for treating cancer with MVA |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6441026B1 (en) * | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
| EA005619B1 (en) * | 2000-02-28 | 2005-04-28 | Авентис Фарма С.А. | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer |
-
2003
- 2003-02-21 IT IT000317A patent/ITMI20030317A1/en unknown
-
2004
- 2004-02-16 JP JP2006502025A patent/JP2006518355A/en not_active Withdrawn
- 2004-02-16 CA CA002516097A patent/CA2516097A1/en not_active Abandoned
- 2004-02-16 EP EP04711372A patent/EP1599210A1/en not_active Withdrawn
- 2004-02-16 BR BRPI0407642-7A patent/BRPI0407642A/en not_active IP Right Cessation
- 2004-02-16 MX MXPA05008879A patent/MXPA05008879A/en unknown
- 2004-02-16 WO PCT/EP2004/050130 patent/WO2004073719A1/en not_active Ceased
- 2004-02-18 TW TW093103888A patent/TW200500073A/en unknown
- 2004-02-20 AR ARP040100529A patent/AR043241A1/en unknown
- 2004-02-20 CL CL200400319A patent/CL2004000319A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1599210A1 (en) | 2005-11-30 |
| BRPI0407642A (en) | 2006-03-01 |
| CA2516097A1 (en) | 2004-09-02 |
| TW200500073A (en) | 2005-01-01 |
| MXPA05008879A (en) | 2005-10-05 |
| JP2006518355A (en) | 2006-08-10 |
| CL2004000319A1 (en) | 2005-04-22 |
| WO2004073719A1 (en) | 2004-09-02 |
| ITMI20030317A1 (en) | 2004-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049985A1 (en) | COMBINATION TREATMENT FOR NON-HEMATOLOGICAL MALIGNAL DISEASES | |
| ES2109899T1 (en) | METHOD, COMPOSITIONS AND KITS TO INCREASE ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS. | |
| AR041725A1 (en) | PREVENTION, TREATMENT OF SINUCLEINOPATIC DISEASE AND PHARMACOLOGICAL COMPOSITION | |
| CO6361942A2 (en) | COMBINATION THERAPY WITH PEPTIDIC EPOXYCETONES | |
| ES2080837T3 (en) | TREATMENT OF STATES AND DISEASES. | |
| AR047841A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE-INFLAMMATORY DISORDERS | |
| UY26456A1 (en) | COMPOUNDS THAT FIX THE G-QUADRUPLEX STRUCTURE OF TELOMERES, TRIAZINS FOR THE APPLICATION OF SUCH COMPOUNDS, THE USE OF SUCH COMPOUNDS AS PHARMACEUTICAL PRODUCTS AND INCLUDING THERAPEUTICAL ASSOCIATIONS. | |
| NO20071426L (en) | Cancer combination therapy including AZD2171 and Imatinib | |
| ATE332136T1 (en) | AGENTS SUCH AS NICOTINAMIDE OR CADPR FOR THE TREATMENT OF SKIN DISEASES | |
| AR042051A1 (en) | COMBINED TREATMENT AGAINST CANCER WITH AN ANTI-CANCERIGENE COMPOUND ACTIVATED BY GLUTATIONA S- TRANSFERASA (GST) AND OTHER TREATMENT AGAINST CANCER | |
| IS6558A (en) | Mixed disease treatment with vasoconstrictor | |
| CO5590913A2 (en) | ANTIVIRICAL COMBINATION THERAPY | |
| BRPI0418157A (en) | allogeneic tumor therapy | |
| BR0316057A (en) | Methods of treating, controlling or preventing specific cancer and a disease associated with unwanted angiogenesis and of reducing or preventing an adverse effect associated with the administration of a second active ingredient and with radiation therapy, hormone therapy, biological therapy or immunotherapy in a patient suffering from a specific cancer, pharmaceutical composition and kit | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| BRPI0413410A (en) | coadministration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer | |
| MX2022016406A (en) | METHODS FOR TREATING CANCER OR VON-HIPPEL LINDAU DISEASE USING A COMBINATION OF A HIF-2 ALPHA INHIBITOR AND LENVATINIB. | |
| AR048806A1 (en) | USE OF CARIOFILENES IN THE PREPARATION OF MEDICINES AND TREATMENT OF BODY INFLAMMATION AND INFLAMMATORY PAIN AFFECTIONS | |
| AR127966A1 (en) | TOPICAL FORMULATIONS OF PI3K-DELTA INHIBITORS | |
| AR048318A1 (en) | ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA | |
| PT1220676E (en) | PREVENTION OF COLORCECTAL CANCER | |
| RU2005131578A (en) | APLIDINE FOR TREATMENT OF MULTIPLE MYELOMA | |
| AR043241A1 (en) | COMBINED THERAPY THAT INCLUDES AN INDOLPIRROL-CARBAZOL DERIVATIVE AND ANOTHER ANTITUMORAL AGENT | |
| BRPI0416266A (en) | method for treating, preventing and / or controlling an asbestos-related disease or disorder in a patient | |
| NO20064753L (en) | combination therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |